Peer-reviewed publications
Take a look at the Optune publications
Unprecedented 5-year survival data for newly diagnosed glioblastoma from the EF-14 trial published in JAMA
Effect of Tumor-Treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.
Journal of the American Medical Association
Stupp R, Taillibert S, Kanner A, et al. 2017;318(23):2306-2316.
Copyright 2017 American Medical Association. All rights reserved.
2017 article from The ASCO Post on the unprecedented 5-year survival results seen with Optune + TMZ in EF-14
‘Out-of-the-box’ approach plus temozolomide extends survival in glioblastoma.
The ASCO Post
Goodman A. http://www.ascopost.com/issues/may-10-2017/out-of-the-box-approach-plus-temozolomide-extends-survival-in-glioblastoma. Updated May 10, 2017. Accessed October 7, 2022.
Interim analysis of the EF-14 trial: Pivotal phase 3 data for newly diagnosed glioblastoma published in JAMA
Maintenance therapy with Tumor-Treating Fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial.
Journal of the American Medical Association
Stupp R, Taillibert S, Kanner AA, et al. 2015;314(23):2535-2543.
Copyright 2015 American Medical Association. All rights reserved.
The EF-11 trial: Pivotal phase 3 data for recurrent glioblastoma published in the European Journal of Cancer
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
European Journal of Cancer
Stupp R, Wong ET, Kanner AA, et al. 2012;48(14):2192-2202.
Copyright 2012 Elsevier. All rights reserved.
Management of dermatologic adverse events
Prevention and management of dermatologic adverse events associated with Tumor Treating Fields in patients with glioblastoma.
Frontiers in Oncology
Lacouture ME, Anadkat MJ, Ballo MT, et al. 2020;10:1045. doi:10.3389/fonc.2020.01045
Copyright © 2020 Lacouture, Anadkat, Ballo, Iwamoto, Jeyapalan, La Rocca, Schwartz, Serventi and Glas.
Results from the NovoTAL™ System User Study
NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study.
World Journal of Surgical Oncology
Chaudhry A, Benson L, Varshaver M, et al. 2015;13:316. doi: 10.1186/s12957-015-0722-3